Aprea Therapeutics (APRE) Current Deferred Revenue (2023 - 2024)
Aprea Therapeutics (APRE) posted quarterly Current Deferred Revenue of $50739.0 for Q2 2024, down 65.81% quarter-over-quarter from $148405.0 in Q1 2024.
Aprea Therapeutics (APRE) Current Deferred Revenue (2023 - 2024) Analysis & Trends
Aprea Therapeutics (APRE) has reported Current Deferred Revenue for 2 consecutive years, with $50739.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Current Deferred Revenue changed N/A year-over-year to $50739.0; the TTM figure through Jun 2024 stood at $50739.0 (changed N/A YoY), while the FY2023 annual figure was $528974.0, changed N/A from the prior year.
- Current Deferred Revenue fell to $50739.0 in Q2 2024 per APRE's latest filing, from $148405.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $528974.0 in Q4 2023 and bottomed at $50739.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 50,739.00 |
| Mar 31, 2024 | 148,405.00 |
| Dec 31, 2023 | 528,974.00 |